SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

Assessment of liver fibrosis and cirrhosis is crucial for the management of patients with chronic hepatitis B. The presence of at least moderate liver fibrosis is an important indication for antiviral ...

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

Discover why combining simvastatin and rifaximin does not offer a clinically meaningful advantage in preventing severe ...

Eating vegetables can help reduce the risk of liver cancer by 65 per cent, according to a study. The study, led by ...

Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 2030Ramat Gan, Israel, Feb. 18, 2025 (GLOBE ...

Can-Fite BioPharma (CANF) announced a significant clinical development: the disappearance of episodes of decompensated liver cirrhosis ...

Innovative therapies and surgical techniques have the potential to transform liver cancer care. People with cirrhosis—a ...

Elevated fat levels in your liver can raise your chances of developing serious health issues, including diabetes, ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.